<DOC>
	<DOCNO>NCT00319449</DOCNO>
	<brief_summary>This study conduct compare efficacy , safety , tolerability ezetimibe 10 mg coadministered atorvastatin 10 mg versus atorvastatin 10 mg Indonesian population primary hypercholesterolemia .</brief_summary>
	<brief_title>Adding Ezetimibe Tablet Ongoing Treatment With Atorvastatin Subjects With High Cholesterol Multiple Coronary Heart Disease Risk Factors ( Study P04060 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Participants must LDLC concentration &gt; = 3.3 mmol/L ( 130 mg/dL ) &lt; = 4.9 mmol/L ( 190 mg/dL ) use Freidewald calculation . Participants must triglyceride concentration &lt; 3.99 mmol/L ( 350 mg/dL ) . Participants must two coronary heart disease risk factor list : Current cigarette smoking Hypertension ( BP &gt; = 140/90 mmHg antihypertensive medication ) Low HDL cholesterol ( &lt; 40 mg/dL ) Family history premature CHD ( CHD male first degree relative &lt; 55 year ; CHD female first degree relative &lt; 65 year ) Age ( Men &gt; = 45 year ; woman &gt; = 55 year ) Participant must currently take atorvastatin 10 mg daily history take 80 % daily dose 6 week prior participate . Participants must liver transaminase ( ALT , AST ) &lt; 50 % upper limit normal , active liver disease , CK &lt; 50 % upper limit normal . Participants must maintain cholesterol lower diet , exercise program , stable weight least 4 week prior study willing continue diet exercise program study . Women receive hormonal therapy , include hormone replacement , estrogen antagonist/agonist , oral contraceptive , must maintain stable dose regimen least 8 week willing continue regimen duration study . Participants meet follow criterion exclude : Body mass index ( BMI = weight [ kg ] /height**2 [ ] ) &gt; = 30 Kg/m**2 . Consume &gt; 14 alcoholic drink per week . Women pregnant nursing . Congestive heart failure define NYHA Class III IV . Uncontrolled cardiac arrhythmia . Coronary heart disease ( CHD ) . Unstable severe peripheral artery disease within 3 month participate Uncontrolled hypertension ( treat untreated ) systolic blood pressure &gt; 160 mm Hg diastolic &gt; 100 mm Hg . Type I Type II diabetes mellitus . Secondary cause hyperlipidemia , secondary hypercholesterolemia due hypothyroidism . Impaired renal function ( creatinine &gt; 2.0 mg/dL ) nephrotic syndrome . Known HIV positive . Cancer within past 5 year ( except successfully treat basal squamous cell carcinoma ) . History mental instability , drug/alcohol abuse within past 5 year , major psychiatric illness adequately control stable pharmacotherapy . Participants follow concomitant medication : Participants medication potent inhibitor CYP3A4 , include cyclosporine , systemic itraconazole , fluconazole , ketoconazole , erythromycin clarithromycin , nefazodone , mibefradil , protease inhibitor large amount grapefruit juice ( &gt; 1 quart/day ) . Participants lipidlowering agent ( atorvastatin ) : niacin ( &gt; 200 mg/day ) Participants counter lipid lower agent fish oil , garlic cholestin Participants oral corticosteroid , unless use replacement therapy pituitary/adrenal disease subject stable regimen least 6 week . Participants currently use psyllium , fiberbased laxative , and/or OTC therapy know affect serum lipid level ( phytosterol margarine ) , stable regimen least 5 week agree remain regimen throughout study . Participant currently use orlistat sibutramine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>